BioCentury
ARTICLE | Company News

MediciNova, University of Colorado deal

January 23, 2012 8:00 AM UTC

The university granted MediciNova exclusive, U.S. rights to ibudilast ( AV411, MN166) to treat post-traumatic brain injury (TBI). The glial cell regulator that suppresses IL-1 beta, tumor necrosis factor (TNF) alpha and IL-6 is in Phase II testing to treat medication overuse headache and completed a Phase Ib/IIa trial to treat opioid-induced withdrawal symptoms. Terms were not disclosed. ...